Prothena reported $283.52M in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.79B 51.25M Sep/2026
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
Akebia Therapeutics USD 342.13M 7.53M Sep/2026
ALKERMES USD 4.44B 42.4M Sep/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Amgen USD 96.05B 409M Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Exelixis USD 2.51B 19.26M Sep/2026
Immunic USD 136.42M 22.75M Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Ionis Pharmaceuticals USD 2.91B 81.91M Sep/2026
MacroGenics USD 318.68M 26.72M Sep/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neurocrine Biosciences USD 5.63B 268.3M Sep/2026
Prothena USD 283.52M 19.06M Sep/2026
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Ultragenyx Pharmaceutical USD 1.19B 77M Sep/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026